Attovia Therapeutics, Inc. Common Stock - Asset Resilience Ratio
Attovia Therapeutics, Inc. Common Stock (ATTO) has an Asset Resilience Ratio of 64.12% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Attovia Therapeutics, Inc. Common Stock (ATTO) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2024–2025)
This chart shows how Attovia Therapeutics, Inc. Common Stock's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see ATTO total asset value.
Liquid Assets Composition Over Time
This chart breaks down Attovia Therapeutics, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Attovia Therapeutics, Inc. Common Stock (ATTO) total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $82.30 Million | 64.12% |
| Total Liquid Assets | $82.30 Million | 64.12% |
Asset Resilience Insights
- Very High Liquidity: Attovia Therapeutics, Inc. Common Stock maintains exceptional liquid asset reserves at 64.12% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Attovia Therapeutics, Inc. Common Stock Industry Peers by Asset Resilience Ratio
Compare Attovia Therapeutics, Inc. Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Attovia Therapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual Asset Resilience Ratio data for Attovia Therapeutics, Inc. Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 67.56% | $112.08 Million | $165.89 Million | +17.12pp |
| 2024-12-31 | 50.43% | $38.69 Million | $76.72 Million | -- |
About Attovia Therapeutics, Inc. Common Stock
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments. The company's products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of… Read more